A selective THR-β agonist, resmetirom, has demonstrated a highly significant reduction in hepatic fat and decreased hepatic inflammation in NASH patients following a 36-week treatment [219]. Here, THRB is linked to metabolic dysfunction-associated steatohepatitis.